unknown
Stage
About
Cutanos develops a targeted immune therapy platform using a ligand-based delivery system to direct mRNA and protein antigens specifically to Langerhans cells via minimally invasive skin administration to enhance vaccine efficacy and reduce side effects.
Explore Cutanos's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.